Celebrex prescriptions plunge after risk found - WSJ

	Tweet

New prescriptions for Pfizer Inc.’s arthritis drug Celebrex fell 56 percent last week after the company released data showing the drug may increase the risk of heart attacks and strokes, the Wall Street Journal reports.

And new prescriptions for naproxen, sold under the brand name Aleve, fell 33 percent after the National Institutes of Health linked it also to possible heart risks, the paper said, citing data from Verispan, a market-research company based in Yardley, Pennsylvania.

The data, based on the dispensing activity of about 55 percent of prescriptions issued in U.S. pharmacies, found that Celebrex’s share of new prescriptions for arthritis drugs dropped to 7.9 percent at the end of last week from 14.9 percent a week earlier.

A drug called Mobic, sold by Boehringer Ingelheim and Abbott Laboratories Inc. is among those picking up patients who are switching from Celebrex, the paper said. Last week Mobic gained 24,088 patients in the U.S., including 13,591 who had been prescribed Celebrex.

------------------
CELEBREX ® is a recent break through in the treatment of osteoarthritis and rheumatioid arthritis. Celebrex ® is being hailed by many as a miracle drug. Celebrex enables people to live more active lives, not limited by arthritis pain.

Order Online Celebrex

RELATED STORIES:
FDA official urged halt to Ketek trial on kids   Long-term use of popular inhalers increases risk of pneumonia for COPD patients   FDA adds restrictions to acne drug   What’s the Difference Between a Brand Name Drug and a Generic Drug?   Online sexual enhancement products risky: FDA   Potential new drug for treating all forms of tuberculosis   Senator Says FDA Trying to Suppress Study on Painkillers   Viagra unlikely to trigger heart attack   Nevada launching Web site for Canada drug imports   Over 60 firms in race for elusive cancer vaccines   Scientists in Kenya to push African vaccine research   Bayer starts selling quick-release aspirin

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]